Celcuity (CELC) Change in Accured Expenses (2016 - 2025)
Celcuity's (CELC) quarterly Change in Accured Expenses came in at $11.1 million in Q4 2025, up 320.93% YoY from $2.6 million in Q4 2024, and up 606.79% on a QoQ basis from -$2.2 million in Q3 2025.
Analysis
Celcuity (CELC) Change in Accured Expenses (2016 - 2025) Analysis & Trends
Celcuity (CELC) has 10 years of Change in Accured Expenses data on file, last reported at $11.1 million in Q4 2025.
- Quarterly Change in Accured Expenses rose 320.93% year-over-year to $11.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.4 million (up 410.72% YoY) and the FY2025 annual result came in at $15.4 million, up 410.72% from the prior year.
- Change in Accured Expenses improved to $11.1 million in Q4 2025, from -$2.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $11.1 million in Q4 2025 to a low of -$5.0 million in Q4 2024.
- A 5-year average of $1.3 million and a median of $731978.5 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2021 — Change in Accured Expenses sank 533.84% — and 2022, when it surged 4232.71%.
- Tracing CELC's Change in Accured Expenses over 5 years: stood at -$76959.0 in 2021, then soared by 1382.46% to $986965.0 in 2022, then surged by 106.69% to $2.0 million in 2023, then plunged by 346.82% to -$5.0 million in 2024, then soared by 320.93% to $11.1 million in 2025.
- The last three Change in Accured Expenses figures came in at $11.1 million (Q4 2025), -$2.2 million (Q3 2025), and $5.8 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 11.12 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | 633,000.00 |
| Dec 31, 2024 | -5.04 Mn |
| Sep 30, 2024 | 3.83 Mn |
| Jun 30, 2024 | 1.92 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Dec 31, 2023 | 2.04 Mn |
| Sep 30, 2023 | 3.02 Mn |
| Jun 30, 2023 | 830,957.00 |
| Mar 31, 2023 | -1.02 Mn |
| Dec 31, 2022 | 986,965.00 |
| Sep 30, 2022 | 1.40 Mn |
| Jun 30, 2022 | 461,913.00 |
| Mar 31, 2022 | 413,499.00 |
| Dec 31, 2021 | -76,959.00 |
| Sep 30, 2021 | 230,179.00 |
| Jun 30, 2021 | -11,177.00 |
| Mar 31, 2021 | -113,763.00 |